SCHEDULE 13G/A: RA Capital Management Affirms 9.9% Stake in 4D Molecular Therapeutics
Beneficial Ownership Amendment
RA Capital Management and its affiliated entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of 4D Molecular Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in 4D Molecular Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially owned 4,564,867 shares of 4D Molecular Therapeutics, Inc. Common Stock.
- This represents 9.9% of the Issuer's class of Common Stock, calculated based on 45,692,709 shares outstanding as of November 12, 2024 (adjusted for a December 6, 2024 share exchange), plus 1,656 shares issuable from Pre-Funded Warrants.
- The RA Capital Healthcare Fund, L.P. directly holds 4,564,867 shares of Common Stock and Pre-Funded Warrants exercisable for up to 3,610,000 shares of Common Stock.
- The Pre-Funded Warrants include a "Beneficial Ownership Blocker" provision, which prevents exercise to the extent that beneficial ownership would exceed 9.99% of the outstanding Common Stock.
- RA Capital Management, L.P. serves as the investment adviser for the Fund and is deemed a beneficial owner, with sole power to vote and dispose of the securities held by the Fund.
- Peter Kolchinsky and Rajeev Shah, as controlling persons of RA Capital Management GP, LLC (the general partner of RA Capital), are also deemed beneficial owners.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G/A) disclosing beneficial ownership. It is factual and compliance-oriented, thus maintaining a neutral sentiment. It reaffirms an existing significant stake rather than indicating a new investment or divestment.
Positives
- A significant institutional investor, RA Capital Management, a firm specializing in healthcare, maintains a substantial and stable stake in 4D Molecular Therapeutics, potentially signaling continued confidence in the company's long-term prospects.
- The filing clarifies the ownership structure and compliance with SEC regulations, providing transparency to the market.
Risks
- The Pre-Funded Warrants held by RA Capital Healthcare Fund, L.P. contain a "Beneficial Ownership Blocker" that limits the exercise of these warrants if it would result in beneficial ownership exceeding 9.99% of the Common Stock outstanding, which could cap their immediate upside from full warrant exercise.
- The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G, which is a legal clarification to avoid certain regulatory implications.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the Issuer's future performance or strategic plans.
Management Comments
- Peter Kolchinsky and Rajeev Shah signed the filing, certifying that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
RA Capital Management is a prominent investment firm focused on the healthcare and life sciences sectors. Their continued significant stake in 4D Molecular Therapeutics, a biotechnology company, aligns with their specialized investment strategy within the industry.
Related Party Transactions
- The filing details the relationships between the Reporting Persons: RA Capital Management, L.P. (investment adviser), RA Capital Healthcare Fund, L.P. (the fund holding the shares), and Peter Kolchinsky and Rajeev Shah (controlling persons of RA Capital Management's general partner). This structure constitutes a related party arrangement for reporting purposes, clarifying how beneficial ownership is attributed among them.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's continued stake in the company, which can influence market perception and investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date as of which 45,692,709 shares of the Issuer's Common Stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-13 | Date of filing of the Issuer's Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-06 | Date of the Fund's exchange of 535,000 shares with the Issuer for the same number of Pre-funded Warrants. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-02-14 | Date of execution and delivery of the Joint Filing Agreement and the filing date of the Schedule 13G/A. |
Keywords
4D Molecular Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pre-Funded Warrants, Biotechnology, Healthcare Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.